These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 11566973

  • 1. Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens.
    Hammerschlag MR, Roblin PM, Bébéar CM.
    J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():25-31. PubMed ID: 11566973
    [Abstract] [Full Text] [Related]

  • 2. Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.
    Felmingham D, Zhanel G, Hoban D.
    J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():33-42. PubMed ID: 11566974
    [Abstract] [Full Text] [Related]

  • 3. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D.
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [Abstract] [Full Text] [Related]

  • 4. Clinical management of respiratory tract infections in the community: experience with telithromycin.
    Quintiliani R.
    Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
    Lorenz J.
    Int J Clin Pract; 2003 Dec; 57(6):519-29. PubMed ID: 12918892
    [Abstract] [Full Text] [Related]

  • 7. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
    Casellas JM, Visser M, Mac Dougall N, Coco B, Tomé G, Gliosca L, Grupo Colaborativo de Telitromicina del Cono Sur.
    Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
    Buxbaum A, Forsthuber S, Graninger W, Georgopoulos A.
    J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
    [Abstract] [Full Text] [Related]

  • 10. Telithromycin: a new ketolide antimicrobial for treatment of respiratory tract infections.
    Yassin HM, Dever LL.
    Expert Opin Investig Drugs; 2001 Feb; 10(2):353-67. PubMed ID: 11178347
    [Abstract] [Full Text] [Related]

  • 11. Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin.
    Leclercq R.
    J Antimicrob Chemother; 2001 Sep; 48 Suppl T1():9-23. PubMed ID: 11566972
    [Abstract] [Full Text] [Related]

  • 12. The ketolides: a critical review.
    Zhanel GG, Walters M, Noreddin A, Vercaigne LM, Wierzbowski A, Embil JM, Gin AS, Douthwaite S, Hoban DJ.
    Drugs; 2002 Sep; 62(12):1771-804. PubMed ID: 12149046
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Telithromycin: an oral ketolide for respiratory infections.
    Bearden DT, Neuhauser MM, Garey KW.
    Pharmacotherapy; 2001 Oct; 21(10):1204-22. PubMed ID: 11601667
    [Abstract] [Full Text] [Related]

  • 18. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections.
    Hammerschlag MR, Sharma R.
    Expert Opin Investig Drugs; 2008 Mar; 17(3):387-400. PubMed ID: 18321237
    [Abstract] [Full Text] [Related]

  • 19. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
    Kohno S, Hoban D, Protekt Surveillance Study Group.
    J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361
    [Abstract] [Full Text] [Related]

  • 20. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
    Fogarty CM, Kohno S, Buchanan P, Aubier M, Baz M.
    J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.